The appeal from a trio of researchers in the United States and Brazil came yesterday as the decision-making body of the World Health Organisation is preparing to discuss the fate of smallpox research later this month.
Stockpiles of the live variola virus -- which causes the illness that includes a bumpy rash and can lead to blindness or death -- are currently held at high-security labs in Russia and the United States.
The opinion article was authored by Inger Damon of the US Centres for Disease Control and Prevention, Clarissa Damaso of Universidade Federale do Rio de Janeiro, and Grant McFadden of the University of Florida College of Medicine.
They said there is a limited supply of vaccines against smallpox, and since those were developed in the 1960s and 1970s they "were associated with what we now consider an unacceptable high rate of adverse events, some severe."
Researchers also want a better understanding of how the virus works, since it only infects people. Animal models of the virus do not accurately mimic the human illness.
The World Health Assembly is scheduled to meet this month to decide whether to destroy the remaining stocks of live variola virus or to allow research to continue.
Expressing concern that opinion may be tilting toward getting rid of the stockpiles, the scientists called the ongoing research "vital."
Smallpox was declared eradicated in 1980 and is the only human disease to have been formally eliminated, according to the WHO.
The last US case was documented in 1949 and the world's last naturally occurring case was in Somalia in 1977.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
